Optimal assessment share structured of Pharmacoeconomics for medical drugs according to minimax criterion

Pharmacy Practice

  • Roza Yagudina1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
  • Alex Borodin2Department of Finance of Sustainable, Plekhanov Russian University of Economics, 117997 Moscow, Russia.
  • Andrey Kulikov1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
  • Marina Protsenko1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
  • Vyacheslav Serpik1Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
  • Irina Vigodchikova3National Research Saratov State University named after N. G. Chernyshevsky, Department of differential equations and mathematical Economics, Saratov, Russia.
  • Anastasia Dubinina4I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.

Volume 22 Issue 1 Pages 1-12

DOI: 10.18549/PharmPract.2024.1.2909

Abstract

Objective: To develop a comprehensive methodology for the optimal assessment of the share of the use of medicines, based on the procedure for ranking drugs according to the pharmacoeconomic point scale and the minimax criterion was applied. Methods: The author’s approach is based on the minimax principle and allows solving the problem of optimizing the pharma drug portfolio based on available data, without the need to obtain the parameters of the Markowitz model associated with correlation analysis of data. Results: The authors obtained the optimal distribution of medicines in group A, B: 37% to 63%, which the authors consider a promising recommendation for a pharmaceutical company. The use of a similar approach, which does not contradict the Markowitz methodology, but allows us to reasonably accept the parameters of the model and give the optimal solution for the share distribution of drugs in medical practice. Conclusion: These mathematical tools, justified and equipped with an alternative confirmation, the minimax task can and should take a significant place in the complex pharma-analytical methodology of the management of large companies supplying concomitant drugs to the Russian and foreign market.

Keywords

  • pharmacoeconomic analysis
  • integrated point scale
  • integrated pharmacoeconomic threshold
  • income sharing
  • Australia’s minimax criterion
Pharmacy Practice

Loading…